0001213900-24-024422.txt : 20240320 0001213900-24-024422.hdr.sgml : 20240320 20240320170944 ACCESSION NUMBER: 0001213900-24-024422 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240320 DATE AS OF CHANGE: 20240320 EFFECTIVENESS DATE: 20240320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unicycive Therapeutics, Inc. CENTRAL INDEX KEY: 0001766140 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813638692 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-508154 FILM NUMBER: 24768527 BUSINESS ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 650-384-0642 MAIL ADDRESS: STREET 1: 4300 EL CAMINO REAL, SUITE 210 CITY: LOS ALTOS STATE: CA ZIP: 94022 D 1 primary_doc.xml X0708 D LIVE 0001766140 Unicycive Therapeutics, Inc. 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA CALIFORNIA 94022 650-351-4495 DELAWARE None None Corporation true Shalabh Gupta 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Executive Officer Director Chief Executive Officer, President and Chairman of the Board of Directors John Townsend 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Executive Officer Chief Financial Officer John Ryan 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Sandeep Laumas 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Sara Kenkare-Mitra 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Gaurav Aggarwal 4300 El Camino Real, Suite 210 Los Altos CA CALIFORNIA 94022 Director Biotechnology Decline to Disclose 06b false 2024-03-13 false true true true false 0 Leerink Partners LLC 39011 None None 53 STATE STREET 40TH FLOOR BOSTON MA MASSACHUSETTS 02109 All States false Piper Sandler & Co. 665 None None 800 NICOLLET MALL SUITE 900 MINNEAPOLIS MN MINNESOTA 55402 All States false 50000000 50000000 0 false 25 3500000 0 A cash fee equal to 7.0% of the gross proceeds. 0 false Unicycive Therapeutics, Inc. /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2024-03-20